As of 2025-10-29, the Intrinsic Value of Oramed Pharmaceuticals Inc (ORMP) is -2.95 USD. This ORMP valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.36 USD, the upside of Oramed Pharmaceuticals Inc is -224.86%.
Based on its market price of 2.36 USD and our intrinsic valuation, Oramed Pharmaceuticals Inc (ORMP) is overvalued by 224.86%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.95 - -2.95 | -2.95 | -224.86% |
| P/E | (9.96) - (10.34) | (10.14) | -529.5% |
| DDM - Stable | (5.59) - (25.75) | (15.67) | -763.9% |
| DDM - Multi | (4.09) - (15.01) | (6.47) | -374.3% |
| Market Cap (mil) | 96.76 |
| Beta | 0.32 |
| Outstanding shares (mil) | 41.00 |
| Enterprise Value (mil) | 80.96 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.72% |
| Cost of Debt | 5.00% |
| WACC | 6.19% |